Blog
Category: Cell and Gene Therapy

Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies

Blog

Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...

A fresh start for advanced therapy clinical trials

Blog

A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...

A true platform is the engine for advanced therapies

Blog

A Vineti technology perspective from Chief Technology Officer Phil Calvin Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader...

Now is the time for proven technology that drives scale

Blog

A Vineti technology perspective from CEO and Co-founder Amy DuRoss   The underlying medical science behind cell and gene therapies continues...

Q&A with Dr. Mike Pellini: the need for advanced software to scale cell and gene therapies

Blog

Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former...

Design for personalized therapies: reframing “delight” as the goal

Blog

Sometimes, in the world of UX and product design, “delight” means getting out of the way. Read about general approaches...

The road ahead for #regenmed

Blog

This fall, it will be 15 years since regenerative medicine faced a crisis of funding and support in the United...

ISCT 2019: data elements in the cell therapy value chain

Blog

I just got back from speaking at the International Society for Cell Therapy annual meeting, where the topic was next-gen data management....

Cell therapy and gene therapy versus cancer: 10 numbers to watch

Blog

ASCO 2019 is here! In 2018, ASCO named CAR-T cell therapy the cancer Advance of the Year, and this year’s ASCO brings more cell...